A-623: Suspended Phase IIb enrollment

Anthera suspended enrollment and dosing in the double-blind, international Phase IIb PEARL-SC trial of subcutaneous A-623 due to cracked vials of the lupus candidate. Anthera said there have been no reports of patient-related side effects or problems with drug administrations attributed to this problem, and there have been no serious adverse events reported in the trial. ...